Details for Patent: 11,141,457
✉ Email this page to a colleague
Which drugs does patent 11,141,457 protect, and when does it expire?
Patent 11,141,457 protects MYCAPSSA and is included in one NDA.
Summary for Patent: 11,141,457
Title: | Oral octreotide therapy and contraceptive methods |
Abstract: | This invention relates to methods of administering oral octreotide therapy to a female subject relating to avoidance of combined oral contraceptives or use of a back-up method for contraception. |
Inventor(s): | Haviv; Asi (Gan-Shlomo, IL), Stevens; Ruth Engle (Long Beach, WA), Dawkins; Jennings Ray (Coats, NC) |
Assignee: | AMRYT ENDO, INC. (Needham, MA) |
Application Number: | 17/135,328 |
Patent Claim Types: see list of patent claims | Use; Device; |
Drugs Protected by US Patent 11,141,457
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chiesi | MYCAPSSA | octreotide acetate | CAPSULE, DELAYED RELEASE;ORAL | 208232-001 | Jun 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHILE AVOIDING CONCOMITANT ADMINISTRATION OF LEVONORGESTREL | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |